M. Scot Roberts, Ph.D., is a distinguished immunologist and vaccine development expert with over 25 years of experience in the biopharmaceutical industry. He earned his doctorate in Immunology from the University of California, San Francisco, and began his career at leading institutions such as the National Institutes of Health (NIH), where he contributed to groundbreaking research on immune responses and vaccine adjuvants. Prior to joining Altimmune, Dr. Roberts held key leadership roles at companies like Vical Incorporated, serving as Vice President of Vaccine Development, where he spearheaded the advancement of DNA-based vaccine platforms for infectious diseases and oncology. His extensive background in translational research has positioned him as a thought leader in immunology, with numerous patents and publications in peer-reviewed journals highlighting his innovative approaches to vaccine design and immunotherapy. Throughout his career, Dr. Roberts has achieved notable milestones, including the successful progression of multiple vaccine candidates through preclinical and clinical stages. At Vical, he led teams that developed novel adjuvants and delivery systems, resulting in partnerships with major pharmaceutical firms and advancements in therapies for diseases like influenza and cancer. His work has been instrumental in securing significant funding and regulatory approvals, demonstrating his ability to bridge scientific discovery with practical application. Dr. Roberts is also an active member of professional organizations such as the American Association of Immunologists, where he has presented on emerging trends in vaccine technology and contributed to industry guidelines. As Chief Scientific Officer at Altimmune Inc., Dr. Roberts oversees the company's research and development pipeline, focusing on intranasal vaccines and peptide therapeutics for infectious diseases, obesity, and liver conditions. Under his leadership, Altimmune has advanced candidates like AdCOVID and T-COVID, leveraging proprietary technologies to enhance immune responses with improved safety profiles. His strategic vision drives collaboration with academic and industry partners, ensuring Altimmune remains at the forefront of innovative immunotherapies that address unmet medical needs.